The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Preliminary results from a first-in-human phase 1 dose escalation trial of ADRX-0706, a next generation Nectin-4 ADC, in subjects with advanced solid tumors.
 
Alexandra Drakaki
Employment - ATHOS THERAPEUTICS (I); ATTICA SCIENCES (I); Dyania Health (I)
Leadership - ATHOS THERAPEUTICS (I); ATTICA SCIENCES (I)
Stock and Other Ownership Interests - Alimera Sciences (I); Athos Therapeutics (I); ATTICA SCIENCES; Dyania Health (I); Kyn therapeutics (I); Moderna Therapeutics (I); PROTEAS BIOANALYTICS (I); Urogen pharma (I)
Consulting or Advisory Role - AstraZeneca; AVEO; Bristol-Myers Squibb; Daichi-Sanchyo; DYANIA HEALTH; EMD Serono; EMD Serono; Exelixis; Infinity Pharmaceuticals; Janssen; Loxo/Lilly; Merck; PACT Pharma; RADMETRIX; Roche/Genentech; Seagen
Research Funding - AstraZeneca (Inst); BMS (Inst); Genentech/Roche (Inst); Immunomedics/Gilead (Inst); Infinity Pharmaceuticals (Inst); Jounce Therapeutics (Inst); Kite/Gilead; Merck Sharp & Dohme (Inst); Pfizer (Inst); Seattle Genetics/Astellas (Inst)
Patents, Royalties, Other Intellectual Property - My significant other has several patents with UCLA, Harvard Medical School, Athos Therapeutics, Proteas Bioanalytics and ATTICA Sciences (I)
Travel, Accommodations, Expenses - AstraZeneca; Lilly; Seagen
 
Justin Call
No Relationships to Disclose
 
Sreenivasa Chandana
Speakers' Bureau - Natera
Research Funding - Abbvie (Inst); Adcentrx Therapeutics (Inst); Amgen (Inst); AstraZeneca (Inst); BMS (Inst); Cardiff Oncology (Inst); Dicephera Pharmaceuticals, Inc. (Inst); Elevation Oncology (Inst); Exact Sciences (Inst); Genentech/Roche (Inst); IDEAYA Biosciences (Inst); IgM Biosciences (Inst); Incyte (Inst); Ipsen (Inst); Janssen (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novocure (Inst); Pfizer (Inst); Qualigen Therapeutics (Inst); Zymeworks (Inst)
 
Jordi Rodon Ahnert
Consulting or Advisory Role - AADi; Amgen; Bridgebio Pharma; Ellipses Pharma; iOnctura; Mekanistic Therapeutics; Merus; Monte Rosa Therapeutics; Sardona Therapeutics
Research Funding - 280Bio (Inst); AADi (Inst); Adcentrix (Inst); Alnylam (Inst); Alterome (Inst); Amgen (Inst); AstraZenneca (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); BioAtla (Inst); BioTheryX (Inst); Blueprint Medicines (Inst); C4 Therapeutics (Inst); Cancer Core Europe (Inst); Debiopharm Group (Inst); Exelixis (Inst); Fog Pharmaceuticals (Inst); Fore Biotherapeutics (Inst); Fusion Pharmaceuticals (Inst); GlaxoSmithKline (Inst); Hotspot Pharma (Inst); Hummingbird (Inst); Hutchison MediPharma (Inst); IDEAYA Biosciences (Inst); Immuneering (Inst); Incyte (Inst); Kelun (Inst); Kinnate Biopharma (Inst); Linnaeus Therapeutics (Inst); Loxo (Inst); MapKure (Inst); Merck Sharp & Dohme (Inst); Merus (Inst); Mirati Therapeutics (Inst); Monte Rosa Therapeutics (Inst); Novartis (Inst); Nuvectis Pharma (Inst); Pfizer (Inst); Relay Therapeutics (Inst); Roche (Inst); Scorpion Therapeutics (Inst); Storm Therapeutics (Inst); Symphogen (Inst); Taiho Pharmaceutical (Inst); Tango Therapeutics (Inst); Tyra Biosciences (Inst); Vall d'Hebron Institute of Oncology/Cancer Core Europe (Inst); Vividion Therapeutics (Inst); Yingli Pharma (Inst)
Travel, Accommodations, Expenses - 280-Biotech; American Society of Medical Oncology; Dava Oncology; ESMO; Loxo; National Taiwan University Cancer Center; STOP Cancer
Other Relationship - Boxer Capital; Chinese University of Hong Kong; Guidepoint Pharmacy; Sequenom; Tang Advisors; Vall d'Hebron Institute of Oncology/Ministerio De Empleo Y Seguridad Social
 
Anthony El-Khoueiry
Honoraria - Agenus; AstraZeneca/MedImmune; Bristol-Myers Squibb; EISAI; Elevar Therapeutics; Exelixis; Merck; Qurient; Roche/Genentech; Senti Biosciences; SERVIER; TERUMO
Consulting or Advisory Role - Agenus; AstraZeneca/MedImmune; Bristol-Myers Squibb; Eisai; Elevar Therapeutics; Exelixis; Genentech; Merck; Qurient; Roche; Senti Biosciences; SERVIER; TERUMO
Research Funding - Astex Pharmaceuticals; AstraZeneca; Auransa; Fulgent Genetics
Travel, Accommodations, Expenses - Affimed Therapeutics
 
Drew Rasco
Research Funding - 23andMe (Inst); Abbvie (Inst); Adcentrx Therapeutics (Inst); Arcus Biosciences (Inst); Ascentage Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Aulos Bioscience (Inst); Boehringer Ingelheim (Inst); Bolt Biotherapeutics (Inst); Bristol-Myers Squibb/Celgene (Inst); Compugen (Inst); Constellation Pharmaceuticals (Inst); Cullinan Oncology (Inst); Eikon Therapeutics (Inst); Flare Therapeutics (Inst); GlaxoSmithKline (Inst); Johnson & Johnson/Janssen (Inst); Kronos (Inst); Merck (Inst); Molecular Templates (Inst); PureTech (Inst); Seven and Eight Biopharmaceuticals (Inst); Surface Oncology (Inst); Takeda (Inst); TD2 (Inst)
 
Benjamin Garmezy
Research Funding - Abbvie (Inst); Accutar Biotech (Inst); Arcus Biosciences (Inst); Arcus Biosciences (Inst); AstraZeneca (Inst); AVEO (Inst); crispr therapeutics (Inst); Eikon Therapuetics (Inst); Envision Pharma Group (Inst); Exelixis (Inst); Flare Therapeutics (Inst); Genentech (Inst); Harbour BioMed (Inst); IDEAYA Biosciences (Inst); Janssen Oncology (Inst); Janux Therapeutics (Inst); Jubilant Therapeutics (Inst); Kineta (Inst); Kinnate Biopharma (Inst); Loxo (Inst); Loxo/Lilly (Inst); MiNK Therapeutics (Inst); Nuvation Bio (Inst); ProfoundBio (Inst); Roche/Genentech (Inst); Takeda (Inst); Teon Therapeutics (Inst); Tmunity Therapeutics, Inc. (Inst); Xencor (Inst); Xencor (Inst); Zenshine (Inst); Zenshine (Inst)
(OPTIONAL) Uncompensated Relationships - Abbvie (Inst); Adaptimmune (Inst); Adicet Bio (Inst); AIQ Global (Inst); Amgen (Inst); Arcus Biosciences (Inst); Arvinas (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); Eisai (Inst); EMD Serono (Inst); Exelixis (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Rondo Therapeutics (Inst); Sanofi (Inst); Seagen (Inst); Xencor (Inst)
 
Guiling Li
No Relationships to Disclose
 
Shudong Zhang
No Relationships to Disclose
 
Yu Chen
No Relationships to Disclose
 
Abraham Fong
Employment - Adcentrx Therapeutics; ALX Oncology
Stock and Other Ownership Interests - Adcentrx Therapeutics; ALX Oncology
Research Funding - Adcentrx Therapeutics; ALX Oncology
 
Pia Challita-Eid
Employment - Adcentrx Therapeutics
Leadership - Adcentrx Therapeutics
Stock and Other Ownership Interests - Adcentrx Therapeutics
Patents, Royalties, Other Intellectual Property - Filed patent applications relating to Discovery of biologic therapeutics.
 
Hui Li
Employment - Adcentrx Therapeutics; Pfizer (I)
Leadership - Adcentrx Therapeutics
Stock and Other Ownership Interests - Adcentrx Therapeutics; Pfizer (I)
 
Ye Guo
Honoraria - BeiGene; Merck Serono; MSD; Roche
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; MSD